Recent developments to share with you

Congratulations! Our Company Honored as "Excellent Enterprise" in the 2018 National Entrepreneurship Competition

2022-09-12


Technology innovation drives great achievements. The biomedical industry finals of the 7th China Innovation & Entrepreneurship Competition concluded in Guangzhou on November 15, 2018. A total of 241 outstanding enterprises from across the country stood out from more than 3,500 biomedical companies through preliminary, semi-final, and final rounds at the local level, advancing to the national finals in Guangzhou. Competing projects covered multiple sub-fields, including innovative medical devices, precision medicine, genetic testing, and new drug R&D. After intense competition, 101 excellent enterprises were selected, along with first, second, and third prize winners.

From registration in May, preparation in June, and then advancing through municipal, provincial, and national competitions, the entire process took over six months. It is fair to say that all enterprises that reached the national finals possessed strong capabilities. It is worth celebrating that our company, a research-based technology enterprise just five years old at the time, achieved excellent results in the group finals and earned the title of "Excellent Enterprise."

Sowing Effort, Harvesting Growth! Looking back at our development since our founding in November 2013, the company has continued to expand. Our current R&D laboratory covers nearly 1,600 square meters, with an R&D team of about 30 people and over 20 projects ongoing. The total value of technology transfer agreements has reached approximately RMB 50 million. In 2018, the company was recognized as a Technology-oriented SME, a High-tech Cultivation Enterprise by both Jiangsu Province and Nanjing City and received multiple invention patents.

Five years is both a snapshot of our journey and a look toward the future. As we celebrate the 5th anniversary of our founding, let us warmly congratulate our company on being named an "Excellent Enterprise" in the 2018 National Entrepreneurship Competition, and look forward to the next five glorious years of Kangchuanji's development!

Keywords:

Related information

Good news keeps pouring in: Jiuzhou Pharmaceutical’s Kangchuanji Pharmaceutical has helped its partner obtain marketing approval for Rosuvastatin–Ezetimibe Tablets (I).

Good news keeps pouring in: Jiuzhou Pharmaceutical’s Kangchuanji Pharmaceutical has helped its partner obtain marketing approval for Rosuvastatin–Ezetimibe Tablets (I).

2026-07-03

Good News | Kangchuanji Pharmaceutical’s Sildenafil Citrate Orally Disintegrating Tablets Have Been Approved for Market Launch

According to the drug approval document delivery information released by the NMPA, sildenafil citrate orally disintegrating tablets manufactured by Nanjing Kangchuanji Pharmaceutical Technology Co., Ltd. have been approved for marketing as a Class 4 generic drug under the new chemical drug registration classification, and are deemed to have passed the consistency evaluation.

2026-06-29

A Strong Start to the New Year – Kangchuanji Achieves Multiple Approvals

The new year begins with a wave of good news. Nanjing Kangchuanji Pharmaceutical Technology Co., Ltd. has made an excellent start, backed by professional expertise. According to NMPA drug approval information, the following products have been approved for marketing or have passed consistency evaluation: Famotidine Injection (2ml:20mg), Saxagliptin and Metformin Hydrochloride Extended-Release Tablets (2.5/1000mg and 5/1000mg), Isosorbide Dinitrate Tablets (5mg), Vitamin B6 Injection (100mg/ml), Cefdinir Granules (50mg/0.5g), and Ambroxol and Clenbuterol Oral Solution (1ml: ambroxol hydrochloride 1.5mg and clenbuterol hydrochloride 1μg). Among these, Isosorbide Dinitrate Tablets are the first in China to pass consistency evaluation. As a partner, Kangchuanji provided solid pharmaceutical R&D services, successfully supporting these drugs through the review and approval process.

2026-03-23